AbbVieABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
201% more first-time investments, than exits
New positions opened: 394 | Existing positions closed: 131
5% more funds holding
Funds holding: 3,448 [Q3] → 3,635 (+187) [Q4]
1.69% more ownership
Funds ownership: 70.35% [Q3] → 72.04% (+1.69%) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 1,479 | Existing positions reduced: 1,380
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
5% less capital invested
Capital invested by funds: $244B [Q3] → $232B (-$12.2B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 207 [Q3] → 165 (-42) [Q4]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Cantor Fitzgerald Carter Gould 29% 1-year accuracy 9 / 31 met price target | 21%upside $210 | Overweight Initiated | 22 Apr 2025 |
Guggenheim Vamil Divan 27% 1-year accuracy 8 / 30 met price target | 23%upside $214 | Buy Reiterated | 17 Apr 2025 |
Morgan Stanley Terence Flynn 24% 1-year accuracy 5 / 21 met price target | 39%upside $241 | Overweight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 12%upside $194 | Neutral Assumed | 8 Apr 2025 |
Wells Fargo Mohit Bansal 30% 1-year accuracy 8 / 27 met price target | 38%upside $240 | Overweight Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 74 articles about ABBV published over the past 30 days









